Swedish Orphan Biovitrum AB (publ)
Research Swedish Orphan Biovitrum AB (publ) (SOBI) on Bullrun: market cap SEK 151.49B, P/E 111.0. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSOBI
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencySEK
- Market capSEK 151.49B
- P/E111.0
- Financial periodQ2 2026
- RevenueSEK 7.84B
- Net incomeSEK 1.10B
- Free cash flowSEK 1.57B
- Gross margin76.7%
Valuation Snapshot
latest market cap is SEK 151.49B; P/E is 111.0.
Peer valuation comparison
Latest P/E is 110.99x versus a Healthcare sector median of 24.61x (351.0% above).
Latest P/E is 110.99x versus a Sweden median of 18.18x (510.4% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 28.24B | n/a | n/a | 77.9% | n/a | SEK 1.04B | SEK 11.50B | SEK 37.72B |
| FY2024 | SEK 26.03B | SEK 3.88B | SEK 7.22B | 77.8% | n/a | SEK 1.14B | SEK 12.41B | SEK 40.29B |
| FY2023 | SEK 22.12B | SEK 2.41B | SEK 3.60B | 77.4% | n/a | SEK 904.00M | SEK 11.36B | SEK 33.87B |
| FY2022 | SEK 18.79B | SEK 2.64B | SEK 4.50B | 74.6% | 8.84 | SEK 1.36B | SEK 2.97B | SEK 26.53B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-09-27 | SEK 151.49B | 111.0 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria;
ETFs that hold Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB (publ) is one of the ten largest holdings of 2 ETFs that investors in Europe can buy, most traded first:
| ETF | Weight | TER |
|---|---|---|
| First Trust Ipox Europe Equity Opportunities UCITS ETF | 6.28% | 0.65% |
| Circa5000 Health & Wellbeing UCITS ETF Class USD Accumulating Shares | 2.33% | 0.49% |
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Swedish Orphan Biovitrum AB (publ)'s market cap?
Swedish Orphan Biovitrum AB (publ)'s market capitalization is SEK 151.49B.
What is Swedish Orphan Biovitrum AB (publ)'s P/E ratio?
Swedish Orphan Biovitrum AB (publ)'s price-to-earnings (P/E) ratio is 111.0.
What does Swedish Orphan Biovitrum AB (publ) do?
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care.